Valeant will take over Bausch+Lomb for $8.7 billion

Valeant Pharmaceuticals International has sealed a definitive agreement for the acquisition of Bausch+Lomb for $8.7 billion. The Candian company will pay $4.5 billion in cash to the current owners, an investor group headed by the private equity firm Warburg Pincus, and another $4.2 billion in cash to reduce Bausch+Lomb's current ...

To continue reading this article subscribe now

Already an Eyewear Intelligence subscriber? Sign in here.


Become a member today for full access from just €6,70 a week!

Buying a membership today will give you:

  • Unlimited access to - all insight and analysis available online
  • Our executive edition of Eyewear Intelligence (Digital Edition) - the must-read for all decision-makers in the industry
  • Weekly E-mail Briefing from the Chief Editor with the lastest analysis and most important industry developments
  • Case studies and best practices on business challenges
  • Guest chronicles, interviews, insights from industry experts and leaders that are shaping the future of the industry
  • Access to over 11,500 articles and analyses in the archive
  • Personal library to save articles and track your key content
  • Powerful search and intuitive navigation

To continue reading this article register now.